Alnylam Pharmaceuticals, Inc. (ALNY) AI Stock Analysis

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing ribonucleic acid interference (RNAi) therapeutics. Its pipeline spans genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, central nervous system disorders, and ocular disorders. Commercial products include ONPATTRO for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Clinical-stage investigational candidates include givosiran, patisiran for transthyretin amyloidosis with cardiomyopathy, and cemdisiran. The company maintains development and commercialization partnerships with Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc.

Between FY2021 and FY2025, annual revenue expanded from $844.3M to $3.71B, marked by 65.2% revenue growth in FY2025. Gross margin stood at 81.8% in FY2025, while operating margin turned positive at 13.5% after reaching -83.9% in FY2021. Alnylam achieved annual net income of $313.7M and EPS of $4.46 in FY2025, following a net income of -$278.2M in FY2024. For the trailing twelve months ending June 30, 2026, revenue totaled $4.80B with an operating margin of 17.9% and EPS of $5.93. In the latest quarter ended June 30, 2026, quarterly revenue growth reached 66.9% year-over-year, while research and development expense totaled $1.32B in FY2025.

As of June 30, 2026, Alnylam held $3.31B in cash and short-term investments and $1.27B in total debt, resulting in net cash of $2.04B. Total assets stood at $5.56B compared to shareholders' equity of $1.35B. Liquidity was supported by a current ratio of 3.05 and a debt-to-equity ratio of 0.94. In FY2025, operating cash flow reached $524.1M and free cash flow was $465.4M, alongside capital expenditures of $58.7M. Over five years, the share count increased 15.4%.

ALNY trades at a trailing P/E of 39.1x, above the 28.9x median of its Nasdaq-100 Healthcare peers. Its forward P/E of 19.7x sits below the peer median of 23.0x, alongside an EV/EBITDA of 28.6x compared to the peer median of 20.9x. The stock carries a price-to-sales multiple of 6.5x, matching the peer median of 6.5x. Over the past year, ALNY fell 51.8%, while SPY gained 16.8%. Over five years, ALNY rose 11.2% compared to an 83.0% return for SPY.

Wall Street coverage consists of 17 Strong Buy, 6 Buy, and 7 Hold recommendations, with 0 Sell and 0 Strong Sell ratings. The mean price target of $368.71 represents an upside of 59.0% from the last close of $231.83 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $5.48B and EPS of $8.94, representing 75.9% EPS growth. Over the last 4 quarters, the company recorded 2 EPS beats. The next earnings date is October 29, 2026.

This page is an AI-written research summary of Alnylam Pharmaceuticals, Inc. (ALNY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALNY income statement, ALNY balance sheet, ALNY key metrics, ALNY analyst forecast, ALNY chart. See the ALNY stock overview for the latest quote and news.